Clinical management of BRCA1 and BRCA2 mutation carriers

Oncogene. 2006 Sep 25;25(43):5825-31. doi: 10.1038/sj.onc.1209881.


The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Breast Neoplasms / genetics*
  • Breast Neoplasms / prevention & control
  • Female
  • Genes, BRCA1*
  • Genetic Carrier Screening*
  • Humans
  • Mutation*
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / prevention & control
  • Risk Reduction Behavior